A systematic review of psychedelic-assisted psychotherapy for mental health: An evaluation of the current wave of research and suggestions for the future.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Recent clinical trials have reported promising results on the clinical benefits of classic psychedelics across a range of psychiatric disorders, including depression.
“Recent clinical trials have reported promising results on the clinical benefits of classic psychedelics across a range of psychiatric disorders, including depression [14].”
From The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol (2022) · cites this paper as [14]
Cited by
Sorted by citations
Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review
Burback, L., Brémault‐Phillips, S., Nijdam, M. J., McFARLANE, A. C., & Vermetten, E. H. G. J. M. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230428091433 · Cited by 232 · see citing works
Psychedelic-Assisted Psychotherapy—A Systematic Review of Associated Psychological Interventions
Cavarra, M., Falzone, A., Ramaekers, J. G., Kuypers, K. P. C., & Mento, C. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.887255 · Cited by 171 · see citing works
Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis
Ko, K., Kopra, E. I., Cleare, A. J., & Rucker, J. J. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.09.168 · Cited by 150 · see citing works
Sweeney, M. M., Nayak, S. M., Hurwitz, E. S., Mitchell, L. N., Swift, T. C., & Griffiths, R. R. (2022) · PLoS ONE · doi:10.1371/journal.pone.0271926 · Cited by 64 · see citing works
Psychosis and psychedelics: Historical entanglements and contemporary contrasts
Friesen, P. (2022) · Transcultural Psychiatry · doi:10.1177/13634615221129116 · Cited by 57 · see citing works
“Recent research has focused largely on anxiety and depression at the end of life, treatment-resistant depression, post-traumatic stress disorder, obsessive compulsive disorder, and smoking cessation (Carhart-Harris et al., 2017; Johnson et al., 2017; Ross et al., 2016; Wheeler & Dyer, 2020).”
BackgroundKotler, S., Mannino, M., Kelso, S., & Huskey, R. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104956 · Cited by 52 · see citing works
“Additionally, both cognitively and neurobiologically, the state of flow shares overlap with other altered states of consciousness, including meditative and psychedelic states, states of traumatic stress, and socalled peak or optimal experiences (Carhart-Harris et al., 2012, 2014; Brandmeyer et al., 2019; Wheeler and D…”
The frontiers of new psychedelic therapies: A survey of sociological themes and issues
Andrews, T., & Wright, K. (2022) · Sociology Compass · doi:10.1111/soc4.12959 · Cited by 42 · see citing works
“A 2020 systematic review documents 43 clinical trials of psychedelic-assisted therapies conducted since 1990 (Wheeler & Dyer, 2020), while Perkins et al.”
BackgroundResultFauvel, B., Kangaslampi, S., Strika-Bruneau, L., Roméo, B., & Piolino, P. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2059796 · Cited by 36 · see citing works
“…Berkovitch et al. 2021; Gandy 2019; Goldberg et al. 2020; Luoma et al. 2020; Muttoni, Ardissino, and John 2019; Romeo et al. 2021, 2020; Sueur 2017; Wheeler and Dyer 2020), there is a need to translate and validate the instruments used for measuring the phenomenology of the psychedelic experience.”
BackgroundA Systematic Review of Participant Diversity in Psychedelic-Assisted Psychotherapy Trials
Haft, S. L., Downey, A. E., Raymond‐Flesch, M., Fernandes‐Osterhold, G., Bradley, E., O’Donovan, A., & Woolley, J. D. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2025.116359 · Cited by 35 · see citing works
How Important Is a Guide Who Has Taken Psilocybin in Psilocybin-Assisted Therapy for Depression?
Earleywine, M., Low, F., Altman, B. R., & Leo, J. A. D. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2047842 · Cited by 32 · see citing works
Presence, Trust, and Empathy: Preferred Characteristics of Psychedelic Carers
Thal, S. B., Engel, L. B., & Bright, S. J. (2022) · Journal of Humanistic Psychology · doi:10.1177/00221678221081380 · Cited by 33 · see citing works
Frymann, T., Whitney, S., Yaden, D. B., & Lipson, J. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.863247 · Cited by 30 · see citing works
Giving Consent to the Ineffable
Villiger, D. (2024) · Neuroethics · doi:10.1007/s12152-024-09545-6 · Cited by 32 · see citing works
“Even though these numbers are preliminary, the analysis of systematic reviews and meta-analyses on PAT point in a clear direction: while PAT’s potential for significant improvement is considerable, its potential for significant worsening due to adverse events is very low [89–91 , 94–”
BackgroundResultRagnhildstveit, A., Jackson, L. K., Cunningham, S. R., Good, L., Tanner, Q., Roughan, M., & Henrie-Barrus, P. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.764112 · Cited by 31 · see citing works
Peacock, C., Mascaro, J. S., Brauer, E., Zarrabi, A. J., Dunlop, B. W., Maples‐Keller, J. L., Grant, G. H., Raison, C. L., Rab, F., & Palitsky, R. (2024) · PLoS ONE · doi:10.1371/journal.pone.0296071 · Cited by 27 · see citing works
Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy
Sekula, A. D., Downey, L. A., & Puspanathan, P. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.813746 · Cited by 27 · see citing works
“The recent revival in research on therapies that use psychedelics highlights a unique set of benefits, along with a unique set of challenges and limitations of this approach (Wheeler and Dyer, 2020; Williams et al., 2021).”
BackgroundMeyer, T. D., Meir, P., Lex, C., & Soares, J. C. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114727 · Cited by 24 · see citing works
Villiger, D. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2357669 · Cited by 24 · see citing works
“…in mental health care and suggest that psychedelics can be safely used in the clinical context (Andersen et al., 2021; Bender & Hellerstein, 2022; Haikazian et al., 2023; Ko et al., 2023; Maia et al., 2022; Romeo et al., 2020; Roscoe & Lozy, 2022; Simonsson et al., 2023; Wheeler & Dyer, 2020).”
Co-design of Guidance for Patient and Public Involvement in Psychedelic Research
Close, J. B., Bornemann, J., Piggin, M., Jayacodi, S., Luan, L., Carhart-Harris, R. L., & Spriggs, M. J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727496 · Cited by 23 · see citing works
“There exist numerous guidelines, frameworks and tools for supporting PPI, however, these do not account for the unique challenges faced in psychedelic research.”
BackgroundInfluentialPhilosophy and classic psychedelics: A review of some emerging themes
Letheby, C., & Mattu, J. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2021.00191 · Cited by 22 · see citing works
Yong, A. S. J., Bratuskins, S., Sultani, M. S., Blakeley, B., Davey, C. G., & Bell, J. S. (2025) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674251315642 · Cited by 21 · see citing works
“However, there are methodological variations in how these systematic reviews have catego-rised dosage, types of therapy accompanying MDMA administration, clinical outcomes and populations included (Wheeler and Dyer, 2020).”
Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review
Estric, C., Duron, T., Kabani, S., & López‐Castromán, J. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251338214 · Cited by 17 · see citing works
“Yet there is considerable heterogeneity in the set and setting parameters in clinical trials (dos Santos et al., 2016; Wheeler and Dyer, 2020).”
Spiritual Benefit from Cannabis
Heide, F. J., Chang, T., Porter, N., Edelson, E., & Walloch, J. C. (2021) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2021.1941443 · Cited by 15 · see citing works
“Cannabis ingestion leads to decreased functional connectivity in the brain’s default mode network (Wall et al. 2019), which has been linked both to therapeutic benefit from psychedelics and to ego dissolution (Wheeler and Dyer 2020).”
BackgroundWolfson, E. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00192 · Cited by 12 · see citing works
Schedule 1 barriers to research in the UK: An in-depth qualitative analysis
Howard, A., Neill, J. C., Schlag, A. K., & Lennox, C. (2021) · Drug Science Policy and Law · doi:10.1177/20503245211049313 · Cited by 12 · see citing works
Johansen, L., Liknaitzky, P., Nedeljkovic, M., Mastin-Purcell, L., & Murray, G. (2022) · Systematic Reviews · doi:10.1186/s13643-022-01930-7 · Cited by 11 · see citing works
“Recent clinical trials have reported promising results on the clinical benefits of classic psychedelics across a range of psychiatric disorders, including depression [14].”
BackgroundThe potential of psilocybin use to enhance well-being in healthy individuals – A scoping review
Wiepking, L., de Bruin, E. J., & Ghiţă, A. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00244 · Cited by 11 · see citing works
“…outcomes not included in the conceptualization of well-being employed in this paper (e.g., empathy or mindfulness), and studies published prior to 1990, as many studies of this “ fi rst wave ” of psychedelic research were criticized for containing methodological fl aws (Wheeler & Dyer, 2020).”
ResultPagán, A. F., Lex, C., Soares, J. C., & Meyer, T. D. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0022 · Cited by 9 · see citing works
“9,10 As psilocybin received ‘‘breakthrough therapy’’ status for the treatment of depression by the U.S. Food & Drug Administration (FDA), we thought it would be timely to investigate medical students’ opinions on psilocybin and PAT in an effort to assess the perceptions of the future generation of…”
Cuerva, K., Spirou, D., Cuerva, A., Delaquis, C. P., & Raman, J. (2024) · European Eating Disorders Review · doi:10.1002/erv.3101 · Cited by 9 · see citing works
Masking Influences: A Systematic Review of Placebo Control and Masking in Psychedelic Studies
Barstowe, A., & Kajonius, P. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2424272 · Cited by 9 · see citing works
“Ethical considerations were also often absent as conducting human research was not subject to the same strict regulation as is currently required (Wheeler and Dyer 2020).”
Korman, B. A. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00246 · Cited by 7 · see citing works
Meyer, T. D., Ibrahim, M., Vale, L., & Soares, J. C. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.12.044 · Cited by 6 · see citing works
Hewitt, T., Amaya, I. A., Beauté, R., Seth, A. K., Schmidt, T. T., & Schwartzman, D. J. (2025) · Neuroscience of Consciousness · doi:10.1093/nc/niaf020 · Cited by 7 · see citing works
“…has reported promising response rates for psychedelic-assisted psychotherapy in controlled settings with screened participants (Luoma et al. 2020; Wheeler and Dyer 2020; Carhart-Harris et al. 2021; Ko et al. 2023), though not all such research has yielded positive results (Kupferschmidt2024).”
Chao, Y., & Horton, J. (2021) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2021.90 · Cited by 5 · see citing works
Argento, E., Goldenberg, S. M., Deering, K., Lavalley, J., Braschel, M. C., Bingham, B., & Shannon, K. (2022) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2022.100044 · Cited by 5 · see citing works
Gayze through the looking glass: The curious absence of queer narratives in psychedelia
Desrochers, S. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00316 · Cited by 5 · see citing works
Willms, J. O., McCauley, B., Kerr, L., Presto, P., Arun, A., Shah, N., Irby, K., Strawn, M., & Kopel, J. J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1020214 · Cited by 6 · see citing works
Schuitmaker, N. (2023) · Research Society and Development · doi:10.33448/rsd-v12i9.43308 · Cited by 4 · see citing works
“Research conducted in various settings using qualitative and/or quantitative methodologies, recognises the value of a facilitator (Breeksema et al., 2020; Wheeler & Dyer, 2020).”
BackgroundResultInfluentialPerspectives of Psychotherapists Regarding Psychedelic Assisted Therapy
Kinahan, S. P., & Wilson, E. J. (2025) · Counselling and Psychotherapy Research · doi:10.1002/capr.12881 · Cited by 4 · see citing works
Altman, B. R., Earleywine, M., & Leo, J. A. D. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2021.2020382 · Cited by 4 · see citing works
Shults, F. L. (2022) · International Journal for the Psychology of Religion · doi:10.1080/10508619.2022.2078591 · Cited by 4 · see citing works
“…2021; Yaden et al., 2021; M. W. Johnson et al., 2019; Lebedev et al., 2015) as well as the therapeutic potential of such experiences (Carhart-Harris & Goodwin, 2017; Doblin et al., 2019; Emerson et al., 2014; Johnson, 2018; Lewis-Healey et al., 2021; Wheeler & Dyer, 2020; Yaden & Griffiths, 2020).”
BackgroundGezon, L. L., & Bartlett, K. (2025) · Anthropology of Consciousness · doi:10.1111/anoc.70010 · Cited by 3 · see citing works
Virtuous drug use in the neoliberal age
Chatwin, C., & Alexander, R. G. (2025) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2024.2443659 · Cited by 3 · see citing works
“Recently, however, there has been a renewed and sustained interest in their effectiveness in treating a full range of psychological disorders such as depression, anxiety, PTSD, addiction, and end-of-life distress (Wheeler & Dyer, 2020).”
Bienemann, B., Barbosa, A. R., da Cruz, L. V. M., Multedo, M., & Mograbi, D. C. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2226414 · Cited by 5 · see citing works
“This fact is in accordance with data that point to mys-tical experiences as one of the possible elements that underpin the therapeutic mechanisms of psychedelics in mental health (Wheeler and Dyer 2020).”
ResultAicher, H., Wicki, I. A., Meling, D., Mueller, M. J., Dornbierer, D., & Scheidegger, M. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251344689 · Cited by 2 · see citing works
“Ayahuasca-assisted therapy might work as a catalyst to support such transformative learning processes in the framework of a process-oriented psychotherapy (Mithoefer et al., 2021; Scheidegger, 2018, 2021b; Wheeler and Dyer, 2020).”
Kratina, S., Strıke, C., Schwartz, R. D., Nayfeh, A., Jopling, S. A., Lo, C., & Rush, B. R. (2025) · Social Science & Medicine · doi:10.1016/j.socscimed.2025.118536 · Cited by 2 · see citing works
Varela, Y. M., Tavares, V. D. D. O., Delgado, L. M., de Faria, H. A. T., Menezes, L. Q., Almeida, R. M., Agrícola, P. M. D., de Carvalho, B. S., Bienemann, B., Falchi-Carvalho, M., et al. (2026) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-02188-5 · Cited by 2 · see citing works
Barco, J. A. V., & Garcia, A. C. M. (2025) · Progress in Palliative Care · doi:10.1080/09699260.2025.2484066 · Cited by 2 · see citing works
Leonard, D., & Brooks, T. R. (2025) · Journal of Humanistic Psychology · doi:10.1177/00221678251330066 · Cited by 2 · see citing works
Johnson, S., & Black, Q. C. (2020) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-020-00398-7 · Cited by 2 · see citing works
“Significant adverse events associated with classic psychedelic use are low, with a recent systematic review finding no serious adverse events long-term (Wheeler and Dyer 2020).”
BackgroundHow Psychedelics Can Increase Moral Concern
Dillion, D., Puryear, C., & Gray, K. J. (2024) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780192844064.013.22 · Cited by 1 · see citing works
Kratina, S., Strıke, C., Schwartz, R. D., Nayfeh, A., Jopling, S. A., Lo, C., & Rush, B. R. (2025) · PLoS ONE · doi:10.1371/journal.pone.0318343 · Cited by 1 · see citing works
Contemplating versus having used psychedelics in bipolar disorder - What makes the difference?
Vale, L. N., Ibrahim, M., Fávaro-Pereira, L., Soares, J., & Meyer, T. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120437 · Cited by 1 · see citing works
Psychedelic-assisted psychotherapy: Clarifying the role of the "psychotherapy"
Jerotić, S., Čolović, O., & Marić, N. P. (2026) · Medicinska istrazivanja · doi:10.5937/medi0-62051 · Cited by 1 · see citing works
Kamal, L., Godsell, P., Mulligan, B. P., Eberspaecher, S., Myint, D., Besemann, M., Minerbi, A., & Gupta, G. (2022) · medRxiv · doi:10.1101/2022.01.14.22269304 · Cited by 1 · see citing works
Psychedelic-Assisted Psychotherapy: A Literature Review
Welch, M. V. (2022) · doi:10.46569/20.500.12680/rv043153s · Cited by 1 · see citing works
A Systematic Review of Participant Diversity in Psychedelic-Assisted Psychotherapy TrialsPreprint
Haft, S. L., Downey, A. E., Raymond‐Flesch, M., Fernandes‐Osterhold, G., Bradley, E., O’Donovan, A., & Woolley, J. D. (2024) · doi:10.31219/osf.io/ewyn2 · Cited by 1 · see citing works
Johansen, L., Liknaitzky, P., Nedeljkovic, M., Mastin‐Purcell, L., & Murray, G. (2020) · Research Square · doi:10.21203/rs.3.rs-121894/v1
SUBJECTIVE EXPERIENCES OF CLASSIC PSYCHEDELIC SUBSTANCES USERS
Bienemann, B. (2022) · doi:10.17771/pucrio.acad.59337
РЕНЕСАНС ПСИХОДЕЛІЧНОЇ ТЕРАПІЇ ТА ЇЇ ЗНАЧЕННЯ ДЛЯ УКРАЇНИ
Matrenitsky, V. L. (2022) · Likarska sprava · doi:10.31640/2706-8803-2022-(3-4)-04
de Barros, M. C. M. (2022) · doi:10.11606/t.5.2022.tde-19042023-123148 · Cited by 1 · see citing works
Kratina, S., Lo, C., Schwartz, R. D., Strıke, C., Jopling, S. A., Nayfeh, A., & Rush, B. R. (2023) · doi:10.31234/osf.io/4gfyd
Masking influences: A systematic review of placebo control and blinding in psychedelic studiesPreprint
Barstowe, A., & Kajonius, P. (2024) · Research Square · doi:10.21203/rs.3.rs-3973393/v1
Russian Geo-Politics in BulgariaPreprint
Matov, A. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4928393
Identification and management of anxious depression in patients with treatment-resistant depression
Hershenberg, R., Rapaport, M. H., & Weischedel, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00029-3 · Cited by 1 · see citing works
Ham, R., Gardner, J., Carter, A., & Liknaitzky, P. (2026) · Psychology and Psychotherapy Theory Research and Practice · doi:10.1111/papt.70098
"Riding the Wave"—Social Work Roles in Psychedelic Therapy Settings: A Scoping Review
Walker, A., Kolomer, S. R., & Mapson, K. W. (2026) · Clinical Social Work Journal · doi:10.1007/s10615-026-01036-w
Insight to Action: The Role of Occupational Therapy in Psychedelic Integration
Elkaiam, G., Thomas, H., & Buford, B. (2026) · Occupational Therapy in Mental Health · doi:10.1080/0164212x.2026.2679671
The purpose of the psychosocial protocol in the psychedelic-assisted therapy: A scoping review
Ferreira, F. G. D. P., Fernandes, J. A. B., Filev, R., da Silveira, D. X., & Fidalgo, T. M. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261453850
Schuman, H. D. M., Mina, R., Barkova, S., Nguyen, T., Deleemans, J. M., & Carlson, L. E. (2026) · Global Advances in Integrative Medicine and Health · doi:10.1177/27536130261459354
“19,20 As evidence for the safety and efficacy continues to expand, 21,22 ensuring providers have both the knowledge and structural support to navigate these challenges becomes increasingly important.”
McAlpine, R. G., Utanğaç, M., Kuc, J., Pankhurst, H., Sellers, A., Kraft, D., Litchy, A., Gupta, N. E., Timmermann, C., Kamboj, S. K., et al. (2026) · Mindfulness · doi:10.1007/s12671-026-02957-w · Cited by 5 · see citing works
Embodied Transformation: Psychedelic Therapy Through the Lens of Merleau-Ponty’s Phenomenology
Ritschel, Z., & Wagoner, B. (2026) · Integrative Psychological and Behavioral Science · doi:10.1007/s12124-026-10029-w
“Administered in controlled settings, psychedelics show significant potential in treating depression (Aday et al., 2020; Wheeler & Dyer, 2020 ; Andersen et al., 2021), with therapeutic outcomes correlating strongly with the occurrence of so-called mystical experiences: states marked by a sense of…”
Breaking psychedelic boundaries in public health: emerging ideas with ancient roots
Bartlett, K., Gezon, L. L., Ward, W. D., & Sears, F. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1923284
- Authors
- Wheeler, S. W., & Dyer, N. L.
- Affiliations
- Western University (CA)
- Venue
- Psychology of Consciousness: Theory, Research, and Practice
- Published
- 2020-09
- Volume
- 7
- Issue
- 3
- Pages
- 279-315
- ISSN
- 2326-5523 (ISSN-L)
- 2326-5531
- OpenAlex
- W3033052133
- Cited by
- 74
- References
- 0
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 11 · 2023: 7 · 2022: 25 · 2021: 5 · 2020: 2
- FWCI
- 3.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychology of Consciousness Theory Research and Practice (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psychedelic-assisted psychotherapy, psychedelics, mental health, treatment efficacy, future research directions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
